Clinically, the expression of the human epidermal growth factor receptor 2 (HER2, also known as the erb-b2 receptor tyrosine kinase ERBB2) has been linked to taxane therapy responses in breast cancer patients (Perez et al., 2005). Here, ERBB2 is linked to breast carcinoma.